SwePub
Sök i LIBRIS databas

  Extended search

id:"swepub:oai:lup.lub.lu.se:97abcac4-919a-410e-bee6-718696f722a6"
 

Search: id:"swepub:oai:lup.lub.lu.se:97abcac4-919a-410e-bee6-718696f722a6" > Patient-reported ou...

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist
  • Christiansen, Sara NysomCopenhagen University Hospital (author)

Patient-reported outcomes in axial spondyloarthritis and psoriatic arthritis patients treated with secukinumab for 24 months in daily clinical practice

  • Article/chapterEnglish2024

Publisher, publication year, extent ...

  • 2024

Numbers

  • LIBRIS-ID:oai:lup.lub.lu.se:97abcac4-919a-410e-bee6-718696f722a6
  • https://lup.lub.lu.se/record/97abcac4-919a-410e-bee6-718696f722a6URI
  • https://doi.org/10.1016/j.semarthrit.2024.152388DOI
  • http://kipublications.ki.se/Default.aspx?queryparsed=id:155142142URI

Supplementary language notes

  • Language:English
  • Summary in:English

Part of subdatabase

Classification

  • Subject category:art swepub-publicationtype
  • Subject category:ref swepub-contenttype

Notes

  • Objectives: In patients with axial spondyloarthritis (axSpA) or psoriatic arthritis (PsA) initiating secukinumab, we aimed to assess and compare the proportion of patients achieving 6-, 12- and 24-month patient-reported outcomes (PRO) remission and the 24-month retention rates. Patients and methods: Patients with axSpA or PsA from 16 European registries, who initiated secukinumab in routine care were included. PRO remission rates were defined as pain, fatigue, Patient Global Assessment (PGA) ≤2 (Numeric Rating Scale (NRS) 0–10) and Health Assessment Questionnaire (HAQ) ≤0.5, for both axSpA and PsA, and were calculated as crude values and adjusted for drug adherence (LUNDEX). Comparisons of axSpA and PsA remission rates were performed using logistic regression analyses (unadjusted and adjusted for multiple confounders). Kaplan-Meier plots with log-rank test and Cox regression analyses were conducted to assess and compare secukinumab retention rates. Results: We included 3087 axSpA and 3246 PsA patients initiating secukinumab. Crude pain, fatigue, PGA and HAQ remission rates were higher in axSpA than in PsA patients, whereas LUNDEX-adjusted remission rates were similar. No differences were found between the patient groups after adjustment for confounders. The 24-month retention rates were similar in axSpA vs. PsA in fully adjusted analyses (HR [95 %CI] = 0.92 [0.84–1.02]). Conclusion: In this large European real-world study of axSpA and PsA patients treated with secukinumab, we demonstrate for the first time a comparable effectiveness in PRO remission and treatment retention rates between these two conditions when adjusted for confounders.

Subject headings and genre

Added entries (persons, corporate bodies, meetings, titles ...)

  • Horskjær Rasmussen, SimonCopenhagen University Hospital (author)
  • Pons, MarionCopenhagen University Hospital (author)
  • Michelsen, BrigitteDiakonhjemmet Hospital,Copenhagen University Hospital (author)
  • Glintborg, BenteUniversity of Copenhagen,Copenhagen University Hospital (author)
  • Gudbjornsson, BjornNational University Hospital of Iceland (author)
  • Grondal, GerdurNational University Hospital of Iceland (author)
  • Vencovsky, JiriInstitute of Rheumatology, Prague,Charles University in Prague (author)
  • Loft, Anne GitteAarhus University Hospital,Aarhus University (author)
  • Rotar, ZigaUniversity of Ljubljana,University Medical Centre Ljubljana (author)
  • Pirkmajer, Katja PerdanUniversity of Ljubljana,University Medical Centre Ljubljana (author)
  • Nissen, Michael J.Geneva University Hospital (author)
  • Baranová, Jana (author)
  • Macfarlane, Gary J. (author)
  • Jones, Gareth T. (author)
  • Iannone, FlorenzoUniversity of Bari Aldo Moro (author)
  • Caporali, RobertoUniversity of Milan (author)
  • Laas, Karin (author)
  • Vorobjov, SigridNational Institute for Health Development, Estonia (author)
  • Giuseppe, Daniela DiKarolinska Institutet,Karolinska Institute (author)
  • Olofsson, TorLund University,Lunds universitet,Reumatologi och molekylär skelettbiologi,Sektion III,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Lund Arthritis Research Group (LARG),Forskargrupper vid Lunds universitet,Rheumatology,Section III,Department of Clinical Sciences, Lund,Faculty of Medicine,Lund University Research Groups(Swepub:lu)med-t_o (author)
  • Provan, Sella AarrestadInland Norway University of Applied Sciences,Diakonhjemmet Hospital (author)
  • Fagerli, Karen MindeDiakonhjemmet Hospital (author)
  • Castrejon, IsabelHospital Gregorio Maranon,Complutense University of Madrid (author)
  • Otero-Varela, Lucia (author)
  • van de Sande, MarleenUniversity of Amsterdam (author)
  • van der Horst-Bruinsma, IreneRadboud University Medical Center (author)
  • Nordström, DanHelsinki University Central Hospital (author)
  • Kuusalo, LauraUniversity of Turku (author)
  • Bernardes, MiguelUniversity of Porto (author)
  • Hetland, Merete LundCopenhagen University Hospital,University of Copenhagen (author)
  • Østergaard, MikkelUniversity of Copenhagen,Copenhagen University Hospital (author)
  • Midtbøll Ørnbjerg, LykkeCopenhagen University Hospital (author)
  • Copenhagen University HospitalDiakonhjemmet Hospital (creator_code:org_t)

Related titles

  • In:Seminars in Arthritis and Rheumatism650049-01721532-866X

Internet link

Find in a library

To the university's database

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Close

Copy and save the link in order to return to this view